Literature DB >> 7329892

Antibiotic blood concentrations in patients successfully treated with tobramycin.

M Fiala, S N Chatterjee.   

Abstract

Thirty-nine patients with severe Gram-negative infections were treated with parenteral tobramycin. Thirty-one (79%) were cured of their infection. Tobramycin was most effective in the therapy of patients with urinary tract infections, arthritis and skin and soft tissue infections and relatively less effective in patients with septicaemia, pneumonia, and osteomyelitis. The infection was cured more frequently in patients who achieved a high ratio between the peak serum concentration of tobramycin and the minimal inhibitory concentration of tobramycin against the pathogenic organism (so-called therapeutic ratio). The ratio was greater than 4.0 in 11 of 13 (85%) assays performed in 12 cured patients, whereas this ratio was achieved in only 3 of 10 (30%) instances in 5 patients in whom the therapy failed (P less than 0.05). The latter group also included a greater proportion of patients with an ultimately fatal illness, such as lung cancer and uraemia, compared to the former successfully treated group. Adverse effects of tobramycin on renal function were transitory. No significant effect of tobramycin on the hearing was observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7329892      PMCID: PMC2426172          DOI: 10.1136/pgmj.57.671.548

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  21 in total

1.  Tobramycin: clinical and microbiological evaluation.

Authors:  E Schoutens; M P Vanderlinden; E Yourassowsky
Journal:  Int J Clin Pharmacol       Date:  1973-11

2.  Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid.

Authors:  M Barza; J Brusch; M G Bergeron; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

3.  Comparative pharmacokinetics of tobramycin and gentamicin.

Authors:  C Regamey; R C Gordon; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

4.  Pharmacology of gentamicin in man.

Authors:  L J Riff; G G Jackson
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Endotracheal gentamicin in bronchial infections in patients with tracheostomy.

Authors:  J Klastersky; C Geuning; E Mouawad; D Daneau
Journal:  Chest       Date:  1972-02       Impact factor: 9.410

6.  Relation between dose and levels of gentamicin in blood.

Authors:  R E Winters; K D Litwack; W L Hewitt
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria.

Authors:  G Jaffe; W Ravreby; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

9.  In vitro activity of tobramycin and gentamicin.

Authors:  M R Britt; R A Garibaldi; J N Wilfert; C B Smith
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

10.  In vitro bactericidal effectiveness of four aminoglycoside antibiotics.

Authors:  P J Hyams; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.